We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+15.57%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$759M
AUM Growth
+$1.33M
Cap. Flow
-$40.4M
Cap. Flow %
-5.32%
Top 10 Hldgs %
61.45%
Holding
63
New
9
Increased
18
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$23.3M
2
IRON icon
Disc Medicine
IRON
+$15.3M
3
CATX icon
Perspective Therapeutics
CATX
+$14.7M
4
MGTX icon
MeiraGTx Holdings
MGTX
+$13.2M
5
QTTB icon
Q32 Bio
QTTB
+$4.95M

Top Sells

Rank Stock Value
1
HROW icon
Harrow
HROW
+$47.2M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$20.1M
3
CGON icon
CG Oncology
CGON
+$17.9M
4
ALKS icon
Alkermes
ALKS
+$13.7M
5
OCUL icon
Ocular Therapeutix
OCUL
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$99.9M 13.15%
2,832,230
-1,072,770
-27% -$47.2M
LQDA icon
2
Liquidia Corp
LQDA
$6.26B
$88.8M 11.7%
2,545,000
+110,000
+5% +$4.08M
ETON icon
3
Eton Pharmaceutcials
ETON
$1.79B
$70.6M 9.3%
2,860,000
– –
SLGL icon
4
Sol-Gel Technologies
SLGL
$238M
$39.6M 5.22%
500,000
+46,261
+10% +$3.34M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.75B
$35.3M 4.65%
123,000
-207,000
-63% -$20.1M
APGE icon
6
Apogee Therapeutics
APGE
$10.2B
$32.8M 4.32%
390,000
+1,743
+0.4% +$127K
IRON icon
7
Disc Medicine
IRON
$3.17B
$26.9M 3.55%
421,000
+221,000
+111% +$15.3M
URGN icon
8
UroGen Pharma
URGN
$2.22B
$25.7M 3.39%
1,430,000
+1,161,577
+433% +$23.3M
CBIO
9
Crescent Biopharma
CBIO
$660M
$24.1M 3.18%
1,312,615
+134,315
+11% +$1.54M
STOK icon
10
Stoke Therapeutics
STOK
$2.1B
$22.8M 3%
700,000
+5,000
+0.7% +$164K
CATX icon
11
Perspective Therapeutics
CATX
$363M
$19.5M 2.57%
4,675,000
+3,490,500
+295% +$14.7M
RZLT icon
12
Rezolute
RZLT
$480M
$19.2M 2.53%
6,300,000
+12,844
+0.2% +$38.5K
MGTX icon
13
MeiraGTx Holdings
MGTX
$1.36B
$18.4M 2.42%
2,123,259
+1,732,415
+443% +$13.2M
TGTX icon
14
TG Therapeutics
TGTX
$8.53B
$17.8M 2.34%
535,000
– –
SNWV
15
SANUWAVE Health Inc
SNWV
$40.1M
$17M 2.23%
981,267
– –
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.8B
$15.8M 2.07%
500,000
– –
ACOG
17
Alpha Cognition
ACOG
$212M
$14.1M 1.85%
2,561,950
+491,166
+24% +$2.79M
ANNX icon
18
Annexon
ANNX
$995M
$12.9M 1.7%
2,331,761
-268,239
-10% -$1.51M
ALMS
19
Alumis Inc
ALMS
$3B
$12.1M 1.6%
550,000
+15,000
+3% +$375K
CDXS icon
20
Codexis
CDXS
$182M
$11.1M 1.46%
6,785,000
-4,738
-0.1% -$6.75K
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.67B
$10.5M 1.39%
100,000
-5,000
-5% -$443K
RVMD icon
22
Revolution Medicines
RVMD
$47.4B
$9.72M 1.28%
100,000
– –
XOMA
23
DELISTED
Xoma
XOMA
$9.41M 1.24%
300,000
+7,410
+3% +$198K
QTTB icon
24
Q32 Bio
QTTB
$481M
$8.06M 1.06%
1,256,228
+1,042,865
+489% +$4.95M
MBX
25
MBX Biosciences
MBX
$3.2B
$7.76M 1.02%
260,000
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2026 Portfolio in Review

As of Q1 2026, Opaleye Management held 63 positions worth $759M, up 0.18% from $758M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management withdrew a net $40.4M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Alkermes, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Editas Medicine worth $4.76M.

  • Opaleye Management's largest Q1 2026 buy was Editas Medicine: 1,926,997 shares worth $4.76M.
  • Opaleye Management added most to UroGen Pharma in Q1 2026, an estimated $23.3M increase.
  • Opaleye Management's biggest Q1 2026 reduction was Harrow, cutting an estimated $47.2M.
  • Opaleye Management fully exited Alkermes in Q1 2026, selling an estimated $13.7M.
  • Opaleye Management's ten largest holdings make up 61% of its $759M portfolio in Q1 2026.
  • Opaleye Management opened 9 new positions and closed 9 in Q1 2026.
  • Opaleye Management's portfolio value rose 0.18% quarter-over-quarter to $759M.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.